CD4 and hepatitis A virus infection: Applying this stringent cut-off to our validation cohort of patients with unresectable metastatic disease (Fig. 2f) allowed us to correctly predict hepatitis in 6 of 6 patients with CD4+ TEM≥21% (specificity = 100%) and correctly identify 6 of 20 patients who developed hepatitis (sensitivity = 30.0%).